Establishment Labs Holdings (ESTA) Tops Q4 EPS by 13c

Go back to Establishment Labs Holdings (ESTA) Tops Q4 EPS by 13c

Establishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023 4:00 PM EST

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States. The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022 and provided 2023 guidance.

Fourth Quarter Highlights and Outlook

Fourth and... More